WASHINGTON D.C.: The U.S. Food and Drug Administration will take more time to evaluate whether e-cigarette maker Juul Labs and other companies can sell their products in the United States.
The Food and Drug Administration was expected to rule this week on a one-year old application by Juul and other e-cigarette brands, including British American Tobacco Plc's Vuse and Imperial Brands Plc's Blu. The e-cigarette companies are required to show that their products provided a net benefit to public health.
Earlier, a federal judge extended a grace period ending September 2021 for the British companies as their applications were being reviewed.
In a Thursday statement, the Food and Drug Administration said it continues to "work expeditiously on the remaining applications," noting that many are "in the final stages of review."
Officials said that the Food and Drug Administration's scientific review of e-cigarettes is meant to determine whether they assist in helping smokers to quit and whether the benefits to smokers outweigh the health damage to new users - including teenagers - who have never smoked.
While e-cigarettes have been available in the United States since 2006, the Food and Drug Administration did not receive jurisdiction over the industry until May 2016.
A 2016 ruling requires e-cigarette makers to file applications to the FDA that demonstrate the public health benefits of their products, along with data about potential toxins.